- Home
- JAZZ vs MTG Comparison
JAZZ vs MTG Comparison
Compare JAZZ & MTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- MTG
- Stock Information
- Founded
- JAZZ 2003
- MTG 1957
- Country
- JAZZ Ireland
- MTG United States
- Employees
- JAZZ N/A
- MTG N/A
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- MTG Property-Casualty Insurers
- Sector
- JAZZ Health Care
- MTG Finance
- Exchange
- JAZZ Nasdaq
- MTG Nasdaq
- Market Cap
- JAZZ 6.7B
- MTG 6.4B
- IPO Year
- JAZZ 2007
- MTG 1991
- Fundamental
- Price
- JAZZ $110.27
- MTG $25.26
- Analyst Decision
- JAZZ Strong Buy
- MTG Hold
- Analyst Count
- JAZZ 12
- MTG 8
- Target Price
- JAZZ $183.08
- MTG $26.88
- AVG Volume (30 Days)
- JAZZ 651.1K
- MTG 2.7M
- Earning Date
- JAZZ 07-30-2025
- MTG 07-30-2025
- Dividend Yield
- JAZZ N/A
- MTG 2.06%
- EPS Growth
- JAZZ 49.21
- MTG 15.33
- EPS
- JAZZ 7.51
- MTG 3.00
- Revenue
- JAZZ $4,064,808,000.00
- MTG $1,219,604,000.00
- Revenue This Year
- JAZZ $6.05
- MTG $2.92
- Revenue Next Year
- JAZZ $4.68
- MTG $3.14
- P/E Ratio
- JAZZ $14.72
- MTG $8.41
- Revenue Growth
- JAZZ 5.76
- MTG 4.64
- 52 Week Low
- JAZZ $95.49
- MTG $21.81
- 52 Week High
- JAZZ $148.06
- MTG $28.67
- Technical
- Relative Strength Index (RSI)
- JAZZ 52.75
- MTG 34.87
- Support Level
- JAZZ $109.27
- MTG $26.13
- Resistance Level
- JAZZ $112.70
- MTG $28.67
- Average True Range (ATR)
- JAZZ 2.72
- MTG 0.58
- MACD
- JAZZ 0.42
- MTG -0.30
- Stochastic Oscillator
- JAZZ 67.81
- MTG 3.13
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About MTG MGIC Investment Corporation
MGIC Investment Corp provides private mortgage insurance, other mortgage credit risk management solutions, and ancillary services. The insurance premiums that these customers pay for the protection accounts for close to majority of the company's total revenue. Investment income accounts for the remaining revenue. The company sells its insurance products in all states of the United States and in Puerto Rico. Its greatest exposure is in California, Florida, Texas, Pennsylvania, Ohio, Illinois, Virginia, North Carolina, Georgia and New York.